The success of allogeneic stem cell transplantation (allo-SCT) in children is mainly affected by relapse or graft rejection. We have recently shown in a study of 55 patients with acute leukemias (ALL 21, AML 20 and MDS 14), that patients who demonstrate increase amounts of autologous marrow repopulation (increasing mixed chimerism) have a significantly enhanced risk of relapse (P Ͻ 0.0001). Based on these findings, we asked whether post-transplant relapse can be prevented by withdrawal of immunosuppression and/or by donor lymphocyte infusion (DLI). We describe the results of a pilot study where adoptive immunotherapy was used to treat 12 patients (five ALL, three AML, four MDS) who showed increasing mixed chimerism (MC) post-transplant. A response to immunotherapy, defined as the re-establishment of complete chimerism (CC) and continuous complete remission (CCR), was achieved in four patients (two ALL, two AML) following withdrawal of CsA and in a further six patients (three ALL, three MDS) after additional DLI. One ALL patient, who initially responded to DLI, developed severe GVHD that required further immunosuppression. GVHD was controlled but this patient subsequently relapsed. Another patient with ALL became a CC but developed an isolated relapse in the bone marrow 260 days later. One patient with MDS developed severe GVHD after DLI and died. Two children (one AML and one MDS) did not show any response to interventional treatment and died due to relapse. Of the 12 patients treated, seven remain in CCR at a median follow-up of 747 days (range 351-1109 days). In summary, these results provide evidence that increasing MC can be used to guide adoptive immunotherapy strategies and that these treatment modalities can be used to prevent relapse in children with acute leukemias or MDS after allo-SCT.
Introduction
Over the past decades, allogeneic stem cell transplantation (allo-SCT) has been performed with increasing success in children with particularly unfavorable acute leukemias. The success of this treatment modality is mainly affected by recurrence of the underlying disease. 1 Further treatment by which long-term remission can be re-achieved is mainly restricted to additional SCT which carries a high procedural mortality. 2, 3 In recent years, alternative approaches aimed at either augmenting or inducing an immunologic graft-versusleukemia (GVL) effect have been used to treat relapsed leukemia after allo-SCT. [4] [5] [6] [7] [8] [9] [10] Such treatment modalities include abrupt cessation 11 and rapid tapering of CsA, 12 administration of cytokines 10, 13 and transfusion of donor lymphocytes with or without cytokines.
14, 15 Although the benefits of immunotherapy for patients with CML is well documented 4, [16] [17] [18] [19] there are fewer reports of successful response in patients with acute leukemias. 6, 7, 20, 21 Moreover, clinical response has mostly been associated with measurable graft-versus-host disease Correspondence: P Bader; Fax: +49 7071 294448 Received 29 October 1998; accepted 2 August 1999 (GVHD), possibly due to high cell doses given in the situation of frank hematological relapse. However, there is evidence that low dose of donor T cells may also induce efficient immunoresponse in patients with small leukemia burden to re-achieve long-term remission.
14, [22] [23] [24] We have recently shown in a study of 55 patients with acute leukemias (ALL 21, AML 20 and MDS 14) , that patients who demonstrate increasing amounts of autologous marrow repopulation (increasing mixed chimerism) have a significantly enhanced risk of relapse (P Ͻ 0.0001). 25, 26 Therefore, we investigated whether it is possible to prevent frank hematological relapse by withdrawal of CsA and/or by administration of low-dose donor lymphocyte infusion (DLI).
Patients and methods

Patients
Twelve children with acute leukemias or MDS who developed increasing mixed chimerism (in-MC) after allo-SCT were admitted to our prospective pilot study. Details of diagnosis, age, stage of the disease, conditioning regimen, stem cell donor type, graft manipulation and GVHD prophylaxis are listed in Table 1 . Patients received allo-SCT at the University Children's Hospital Tü bingen, Germany in the period between December 1996 and May 1998. Informed consent of patients and parents where appropriate was obtained according to institutional guidelines. All data were analyzed up to March 1999.
Methods
Determination of individual hematopoietic chimerism at a given time-point was performed by a semiquantitative PCR approach based on amplification of VNTR and STR markers as described previously. A panel of seven VNTR and STR markers (F13A1,  28 TOPIP,   29   1P32,  30 D11S533,  31 IL2Rb,  32 D1S80  33 and D17S30  34 (Table  2) was employed in the initial screening process to identify an informative locus between pretransplant donor and recipient DNA. PCR was performed in a final volume of 50 l, containing 250 ng DNA, 10 mm Tris buffer (pH 8.0), 50 mm KCL, 1.5 mm MgCl 2 , 0.1 mg/ml gelatin, 200 m dNTPs (Boehringer Mannheim, Mannheim, Germany) and 2.5 U TAQ polymerase (Qiagen, Hilden, Germany) and 2 mol of primer (Roth, Karlsruhe, Germany). Cycling parameters were optimized as follows: for primers 1, 2, 3, 6 and 7; 94°C, 60 s; 58°C, 30 s; 72°C, 90 s for 35 cycles and for primers 4 and 5; 94°C, 60 s; 65°C, 30 s; 72°C, 90 s for 35 cycles (Thermocycler 60; Biomed, Theres, Germany). PCR products were resolved on 8% non-denaturing PAGE gel and following staining with ethidium bromide (10 mg/ml) were directly digitalized under UV light stimulation using a CS-1 Videoimager (Cybertech, Berlin/Germany). Gel images were analyzed densitometrically using the WincamR software (Cybertech).
26,27
Amplimers and PCR conditions
Sensitivity of the primers
The sensitivity of detection of the minor population for each VNTR and STR marker was assessed by mixing pretransplant recipient and donor DNA in dilution experiments. Detection levels were found to be influenced by a number of features including the size differential between donor and recipient alleles, the number of alleles present and whether the donor or the recipient alleles were shorter in length. An index of informativity for each marker was calculated from their use in the analysis of hematopoietic chimerism in a group of 100 patients transplanted in this transplant center. Detection levels and an index of informativity for each of the markers are summarized in Table 3 . Table 3 Primer characteristics (2) Lab. Name Sensitivity to detect Frequency of primers No.
recipient DNA in donor used in 100 patients DNA in percent for serial analysis of (min -max -average) post-transplant samples 
Figure 1
Standard curves were generated by mixing pretransplant recipient DNA and donor DNA in a range of percentages. After amplification and densitometric analysis a quotient recipient/donor DNA was calculated. This quotient was referred to the relative amount of recipient DNA and standard curves for the individual patients could be performed. The standard curve of patient UPN 12 is given.
Standard curves
Standard curves were generated for each patient by mixing pretransplant recipient and donor DNA in dilution experiments (dilution range from 75% to 0.8% in relation to donor DNA). All PCR products were processed as described above. The peak area of recipient and donor signals were calculated densitometrically and the proportion of recipient DNA was expressed according to the quotient: peak area recipient peak area donor = quotient recipient/donor DNA.
Mixing experiments were carried out in duplicate and individual standard curves were generated from mean values ( Figure  1 ). The percentage of MC seen in a patient's post-transplant sample was calculated relative to that patient's standard curve. When analysis was performed in multiple parallel reactions where the quotients calculated were found to vary by less than 10% inter and intra assay variations were corrected by the calculation of the recipient/donor quotient ( Figure 2 ). This procedure provides a highly reproducible method for the quantitation of chimerism post-transplant. Using this method it is possible to clearly discriminate changes of the amount of autologous DNA present. All post-transplant samples were interpreted in relation to samples taken from the previous two time-points. An indicative increase in MC was documented according to the following criteria. If the previous analysis showed autologous DNA of less than 10% then an increase of greater than 5% was required. If the previous analysis showed autologous DNA of more than 10% then an increase of greater than 10% was required. An indicative decrease in MC was documented according to the following criteria. If the previous analysis showed autologous DNA of less than 10% then a decrease of greater than 5% was required. If the previous analysis showed autologous DNA of more than 10% then a decrease of greater than 10% was required.
Analysis of post-transplant samples
Post-transplant samples were investigated weekly during the first 100 days after allo-SCT and monthly thereafter. If a patient developed MC, we intensified the monitoring regimen by analyzing samples weekly. Each PCR analysis included DNA from the post-transplant sample of interest, DNA's from the previous two analysis points and pretransplant recipient and donor control samples. Densitometric analysis and the calcu-
Figure 2
An example of multiple parallel reactions of the sample is given. Patient sample of day +54 from patient UPN 12 is amplified. Densitometric analysis of the recipient area under the curve revealed an intrinsic variability of less than 10%. lation of recipient/donor quotient of the post-transplant samples was performed as described above. The percentage autologous DNA was calculated relative to the individual patient's standard curve.
Criteria for initiation of immunotherapy
Patients after allo-SCT who were receiving CsA when increasing mixed chimerism was identified had immunosuppression withdrawn immediately. The chimeric status of these patients was evaluated weekly thereafter. If the amount of autologous DNA decreased subsequently this was taken as an indicator of a patient's response to the therapy. Patients who nonetheless developed a further increase of MC despite cessation of CsA were then given a DLI. Patients who were not receiving CsA when increasing MC was identified were given DLI as firstline treatment. The cell dose administered was adapted to the individual number and potential severity of HLA mismatch known between donor and recipient. Cell doses given varied between 2.5 × 10 4 and 1 × 10 7 /kg body weight. The chimeric status of all patients who received DLI was evaluated weekly. Patients who showed a further increase of MC received additional DLI after a time span of at least 2 weeks after first DLI. A general scheme of treatment modalities is shown in Figure 3 .
Definition of response
Response was defined as a return to the CC status and continuous complete remission (CCR).
Assessment of GVHD
Clinical grading of GVHD was performed according to Refs 35 and 36.
Figure 3
Scheme of immunotherapy. For more information see text. /kg body weight donor lymphocytes on day 41. However, the amount of autologous DNA increased and therefore this patient was considered not to have responded to this first DLI. Therefore an additional 1 × 10 6 /kg donor cells were administered on day 54. Leukemic blasts appeared in the peripheral blood on day 65 and the amount of autologous DNA further increased to 50-60%. At this time-point 1 × 10 7 /kg donor cells were transfused. Autologous patterns of DNA decreased and on day 101 CC was re-established. Unfortunately, the patient developed fatal aGVHD and died on day 184 post-transplant. Figure 4 shows the post-transplant analysis for this patient.
Results
Response and survival
Three patients with ALL (UPN 3, UPN 4 and UPN 5) and one patient with MDS (UPN 11) were transplanted with CD34 + positive enriched peripheral stem cells and did not receive CsA prophylaxis. These patients received DLI as first-
Figure 4
Analysis of post-transplant chimerism in patient UPN 12 using locus D11S533. Recipient (R) and donor (D) specific samples were analyzed together with post-transplant samples. After recurrence of autologous DNA on day 41, the patient was transfused with 1 × 10 6 /kg body weight donor lymphocytes. The amount of autologous DNA further increased. Additional 1 × 10 6 /kg donor cells were administered after day 54. Leukemic blasts appeared in the peripheral blood on day 65 and the amount of autologous cells further increased to 50-60%. Then, 1 × 10 7 /kg donor cells were transfused. On day 101 complete chimerism was re-established. Unfortunately, the patient developed fatal aGVHD and died on day 184 post-transplant.
line treatment when increasing MC was identified. Patients UPN 3 and 5 responded to low-dose DLI (see Table 4 ), reverted to CC. Patient UPN 5 remains in CCR, whereas patient UPN 3 developed an isolated medullar relapse on day +306. Patient UPN 4 who was not in remission when he received allo-SCT with haploidentical stem cells was given two infusions with 1 × 10 5 /kg donor lymphocytes after having developed increasing MC. The patient responded to therapy but developed severe GVHD that required immunosuppressive therapy with CsA, methylprednisolone and OKT 3. Acute GVHD was controlled but the patient progressed to frank hematological relapse and died on day 275 post-transplant. Patient UPN 11 (MDS) showed increasing MC and DLI was started. As she did not respond to first DLI application three additional donor lymphocyte transfusions with 1 × 10 5 /kg cells were given. The patient finally responded to DLI and subsequently reverted to CC. This patient remains in CCR without any sign of GVHD (Fig. 5) .
Time from treatment to response
Patients who responded to cessation of CsA as first-line therapy on the basis of increasing MC generally showed a decrease of autologous DNA in the peripheral blood after 1 week. Patients who showed response to DLI transfusion showed a decrease of autologous DNA between 1 and 2 weeks later.
Toxicity and GVHD
None of the patients showed signs of GVHD when increasing MC was detected. After immunotherapy 6/12 patients developed a certain degree of aGVHD. Patients receiving DLI were more likely to develop GVHD than those patients receiving CsA withdrawal alone. Three patients UPN 1, UPN 4 and UPN 12 developed aGVHD grades III and IV which required additional immunosuppressive treatment. Patient UPN 1 with ALL developed aGVHD III after cessation of CsA. GVHD could be controlled by administration of methylprednisolone and the patient remained a CC. UPN 4 developed aGVHD grade IV after DLI that required immunosuppressive therapy with CsA and OKT 3. GVHD was controlled but the patient progressed to frank hematological relapse and died. Fatal aGVHD occurred in patient UPN 12 after the third infusion of donor lymphocytes. In general, no myelosuppression, prolonged pancytopenia or bone marrow aplasia was seen in any patient.
Discussion
Immunotherapy by transfusion of donor lymphocytes with or without application of cytokines has become the treatment of choice for patients with CML relapsing after allo-SCT. Several studies have been published reporting complete response rates between 60 and 80%. 19, 38 Studies using escalating doses of DLI showed that response to immunotherapy could be achieved without inducing severe GVHD. 16, 17 However, the success of such treatment modalities in patients with CML generally depends on the degree of leukemia burden when treatment is initiated. van Rhee et al 24 demonstrated that therapeutic intervention by donor lymphocyte transfusion in CML patients is more effective before the onset of hematological relapse. There are also data showing that the abrupt discontinuation of post-transplant immunosuppression can restore remission in CML patients.
11
Although several reports have been published, the efficiency of immunotherapy in patients with acute leukemias is still a matter of some debate. 5, 6, 14, 20, 39 Evidence supporting the hypothesis of a graft-versus-leukemia reaction in patients with ALL can be seen in the higher incidence of relapse that is observed in patients who do not develop GVHD 40 and in patients who receive T cell-depleted allografts. 41 The first report of the successful implementation of DLI was described by Slavin et al 20, 22 in a patient suffering from relapse of ALL following allo-SCT. Mehta et al 6 have recently described responses to allogeneic cell therapy in patients with CML and also acute leukemias.
There is considerable evidence showing that the benefit of immunotherapy is greatest if treatment is implemented before hematological relapse has occurred. 14,22,24 Therefore, attempts have been made at highlighting patients who are at greatest risk of relapse in whom the implementation of additional immunotherapy to prevent frank hematological relapse would be entirely justified. Hancock et al 42 have shown that patients with persistent mixed chimerism at day +28 have a significantly enhanced risk of relapse and Powles et al 43 highlighted patients with slow lymphocyte recovery who are associated with a highest risk for relapse. We have previously shown a highly significant correlation between the presence of increasing mixed chimerism and relapse in patients transplanted for acute leukemias and MDS. 26 In the current study we offered additional immunotherapy to patients with acute leukemias who developed increasing MC post-transplant. Of the 12 patients who were studied, 10 patients showed an initial response to immunotherapy, and eight patients converted to CC and remained in CCR. Only 1/5 patients with ALL relapsed despite additional treatment. These data further substantiate ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CC, complete chimerism after DLI but the patient relapsed 252 days after DLI; CR, complete remission; CsA, cyclosporin A; DLI, donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; inMC, increasing mixed chimerism; IS**, immunosuppression after DLI (see text); MFD, matched family donor; MMFD, mismatched family donor; MUD, matched unrelated donor; UPN, unique patient number.
Figure 5
Analysis of post-transplant chimerism in patient UPN 11 using locus D17S30. Recipient (R) and donor (D) specific samples were analyzed together with post-transplant samples. After recurrence of 1-5% autologous DNA on day +40 the patient was transfused with 1 × 10 5 /kg body weight donor lymphocytes on day +51 when autologous patterns reached 10-15%. The amount of autologous DNA did not decrease and additional 1 × 10 5 /kg donor cells were administered after day 65. When autologous DNA further increased to 30-40% on day 76 again 1 × 10 5 /kg DLI were transfused. The patient did not develop GVHD and a last donor cell transfusion was given on day 90. CC was re-established on day 140 and the patient remained in CCR.
the hypothesis of a graft-versus-leukemia effect in patients with acute myeloid and lymphoblastic leukemias.
It was the aim of this pilot study to investigate whether the cessation of post-transplant immunosuppression and/or lowdose donor lymphocyte infusions could be used to convert patients to CC and keep them in CCR. Our data show that prophylactic immunotherapy can result in prolonged leukemia-free survival in children with acute leukemia and MDS. Starting treatment in an early phase offers the possibility to use CsA cessation or low-dose DLI and therefore lower the risk of inducing severe aGVHD. 37 Four of the patients who remain in CCR responded to cessation of cyclosporine alone. One patient with Ph + positive ALL developed aGVHD grade III that could be controlled by methylprednisolone without reappearance of minimal residual disease. Withdrawal of CsA is a simple and effective way to reinduce or augment clinical GVL effects 14,15,37 but one should keep in mind the risk of rapidly emerging aGVHD even in children. Two out of 12 patients developed aGVHD grade IV after DLI ranging between 1 × 10 5 /kg (three antigens mismatched related donor) and 1 × 10 7 /kg (matched unrelated donor). This confirms previous data that a threshold of 1 × 10 5 /kg donor cells per kilogram is considered sufficient to cause aGVHD and to induce a graft-versus-leukemia effect during the immediate post-BMT phase.
14, 16, 17 Due to the low numbers of patients involved in this study and also the variety of their diagnoses, it is not possible to drawn final conclusions regarding the optimal dose and schedule for adoptive immunotherapy for the treatment of relapse. It is our experience that responses to the cessation of CsA can be documented 1 week after stopping immunosuppression and between 1 and 2 weeks after administration of DLI. Responses were clearly indicated by a decrease of autologous DNA (decreasing mixed chimerism) in the peripheral blood. To circumvent fatal GVHD prophylactic immunotherapy should be guided individually and cell doses adjusted according to the degree of HLA mismatch between donor and recipient. Serial analysis of chimerism using a semiquantitative PCR-based technique offers the possibility of documenting response and presents a rational basis for treatment intensification in patients who did not respond to first-line treatment.
Further therapy for patients with acute leukemias who relapse after allo-SCT is always difficult whether it is immunotherapy or a second transplant. Our data show evidence that prophylactic immunotherapy on the basis of increasing mixed chimerism in patients with acute leukemias offers the possibility to prevent frank hematological relapse with a tolerable rate of mortality and morbidity. However, further studies will be required to optimize treatment strategies and reveal the optimal dose of lymphocyte infusions according to the individual donor/recipient constellation.
